The specific impact of DNMT3A mutations in allogeneic stem cell transplantation is unclear, although clinical data suggest that donor DNMT3A mutations are associated with increased graft-versus-host disease, reduced recurrence, and improved survival [88, 89]. This evidence concerns the gene DNMT3A and graft versus host disease.